Sites
Tags
- A
- Accelerated approval
- Asset
- Biopharmaceutical
- Biotechnology
- Chief financial officer
- Chief operating officer
- Diversity
- Diversity and inclusion
- Earnings before interest and taxes
- Edgar
- Enzyme replacement therapy
- Epidermolysis bullosa
- Equity
- Forbes
- GlaxoSmithKline
- Glycogen storage disease type II
- Inclusion
- Initial public offering
- International Standard Book Number
- John Crowley
- Lysosomal storage disease
- Manufacturing
- MarketWatch
- NASDAQ
- Net income
- New drug application
- New Enterprise Associates
- Notre Dame
- Philadelphia
- President
- Priority review
- Public company
- Rare disease
- Royal Society of Chemistry
- Russell 2000 Index
- San Diego
- Scott Gottlieb
- Seeking Alpha
- Shire
- Ticker symbol
- University
- University of Notre Dame
- U.S. Securities and Exchange Commission
- Venture capital financing